Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cyclophosphamide + doxorubicin + vincristine
- Development stage
- Unknown
- Lead developer
- Bristol Myers Squibb
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
Cyclophosphamide + doxorubicin + vincristine is a combination chemotherapy regimen commonly referred to as CAV. It consists of three cytotoxic agents: - **Cyclophosphamide**: an alkylating agent that interferes with DNA replication and RNA transcription, leading to cell death. - **Doxorubicin**: an anthracycline antibiotic that intercalates into DNA and inhibits topoisomerase II, preventing DNA replication and repair. - **Vincristine**: a vinca alkaloid that binds to tubulin and inhibits microtubule formation, arresting cells in metaphase during mitosis. This combination is used primarily for the treatment of small cell lung cancer (SCLC), particularly in extensive disease settings. It has also been studied or used in other cancers such as lymphomas. The drugs act synergistically by targeting different cellular processes essential for cancer cell survival[5][8].
- Other names
- CAV
02
Targets
TOP2A (DNA topoisomerase II)DNAMicrotubule
Beyond the preview
Go deeper on cyclophosphamide + doxorubicin + vincristine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on cyclophosphamide + doxorubicin + vincristine.